P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

July 2014

Features

New U.S. Drug Tracing Regimen Stirs Concern

Pharmacies Will Have Options ... and Costs

The FDA is trying to decide how to implement a new law by January 1, 2015, that requires manufacturers, wholesalers, and pharmacies to trace drug products as they move through the distribution chain. A degree of turmoil appears likely to result.
Stephen Barlas

Social Media and Health Care Professionals: Benefits, Risks, and Best Practices

Health care professionals can use a variety of social media tools to improve or enhance networking, education, and other activities. However, these tools also present some potential risks, such as unreliable information and violations of patients’ privacy rights.
C. Lee Ventola

CFTR Modulators for the Treatment of Cystic Fibrosis

Defects in a single gene lead to the defective proteins that cause cystic fibrosis, making the disease an ideal candidate for mutation-targeted therapy. Although ivacaftor is currently the only FDA-approved CFTR modifier, others are in development.
Rebecca S. Pettit, PharmD, MBA, BCPS; and Chris Fellner

Meeting Highlights

American Society of Clinical Oncology

The American Society of Clinical Oncology meeting drew more than 34,600 people to Chicago to learn about the latest research, including studies on lymphoma, pancreatic cancer, colon cancer, melanoma, multiple myeloma, and palliative care.
Walter Alexander

Pipeline Plus

Huge Growth Seen in Hepatitis C Market

As better drugs from a variety of pharmaceutical industry players enter a market with millions of untreated patients, U.S. spending on hepatitis C treatments is expected to rise from $2.1 billion in 2012 to $6.5 billion in 2022.
Kunj Gohil, PharmD, RPh

Departments

Medication Errors

Ingestion or Aspiration of Foreign Objects or Toxic Substances Is Not Just a Safety Concern With Children

Take steps to prevent ingestion or aspiration of objects
Matthew Grissinger, RPh, FaScP

Prescription: Washington

Medicare Backs Off on MTM Changes

Congressional and Patient-Group Opposition to Other, More Controversial Part D Reforms Sank the Plan

Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Pharmaceutical Approval Update

Albiglutide (Tanzeum) for type-2 diabetes, ramucirumab (Cyramza) for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, and ceritinib (Zykadia) for metastatic non–small-cell lung cancer
Marvin M. Goldenberg, PhD, RPh, MS

Drug Forecast

Ibrutinib (Imbruvica): A Novel Targeted Therapy for Chronic Lymphocytic Leukemia

Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia
Sapna Parmar, PharmD; Khilna Patel, PharmD; and Javier Pinilla-Ibarz, MD, PhD